KNSA insider transaction filings
Kiniksa Pharmaceuticals International, plc — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-21. Screen KNSA transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-21 | 4 | Quart Barry D — Director | Gift (G): 2,600 @ $0 | EDGAR |
| 2026-08-04 | 4 | Levy Richard S — Director | Option exercise (M): 403 · Grant/award (A): 403 (derivative) @ $0 · Option exercise (M): 403 (derivative) @ $0 | EDGAR |
| 2026-07-31 | 4 | Cole G Bradley — Director | Sale (S): 3,673 @ $81.43 · Gift (G): 4,500 @ $0 | EDGAR |
| 2026-07-06 | 4 | Malkani Dhiraj H — CHIEF STRATEGY OFFICER | Grant/award (A): 82,600 (derivative) @ $0 · Grant/award (A): 14,000 (derivative) @ $0 · Grant/award (A): 2,119 (derivative) @ $0 · Grant/award (A): 2,188 (derivative) @ $0 · Grant/award (A): 1,245 (derivative) @ $0 · Grant/award (A): 1,307 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | McCain Tracey L — Director | Option exercise (M): 2,799 · Grant/award (A): 12,158 (derivative) @ $0 · Grant/award (A): 2,026 (derivative) @ $0 · Option exercise (M): 2,799 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Patel Sanj K — CHAIRMAN & CEO, Director | Conversion (C): 900,000 · Conversion (C): 900,000 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Levy Richard S — Director | Option exercise (M): 2,799 · Grant/award (A): 12,158 (derivative) @ $0 · Grant/award (A): 2,026 (derivative) @ $0 · Option exercise (M): 2,799 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Malley Thomas — Director | Option exercise (M): 2,799 · Grant/award (A): 12,158 (derivative) @ $0 · Grant/award (A): 2,026 (derivative) @ $0 · Option exercise (M): 2,799 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Quart Barry D — Director | Option exercise (M): 2,799 · Grant/award (A): 12,158 (derivative) @ $0 · Grant/award (A): 2,026 (derivative) @ $0 · Option exercise (M): 2,799 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Cole G Bradley — Director | Option exercise (M): 2,799 · Grant/award (A): 12,158 (derivative) @ $0 · Grant/award (A): 2,026 (derivative) @ $0 · Option exercise (M): 2,799 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Popovits Kimberly J — Director | Option exercise (M): 2,799 · Grant/award (A): 12,158 (derivative) @ $0 · Grant/award (A): 2,026 (derivative) @ $0 · Option exercise (M): 2,799 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | BAKER BROS. ADVISORS LP — Director 667, L.P. — Director Baker Bros. Advisors (GP) LLC — Director Baker Brothers Life Sciences LP — Director BAKER FELIX — Director BAKER JULIAN — Director | Grant/award (A): 6,078 @ $0 · Grant/award (A): 6,078 @ $0 · Grant/award (A): 36,474 (derivative) @ $0 · Grant/award (A): 36,474 (derivative) @ $0 | EDGAR |
| 2026-05-05 | 4 | Paolini John F. — CHIEF MEDICAL OFFICER | Option exercise (M): 58,424 @ $10.36 · Sale (S): 37,327 @ $53.52 · Sale (S): 21,097 @ $54.04 · Option exercise (M): 58,424 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Patel Sanj K — CHAIRMAN & CEO, Director | Option exercise (M): 48,565 @ $30.93 · Sale (S): 48,565 @ $54.02 · Option exercise (M): 48,565 (derivative) @ $0 | EDGAR |
| 2026-04-30 | 4 | Patel Sanj K — CHAIRMAN & CEO, Director | Option exercise (M): 431,904 @ $10.36 · Option exercise (M): 51,750 @ $30.93 · Sale (S): 74,635 @ $50.43 · Sale (S): 113,673 @ $51.47 · Sale (S): 243,596 @ $52.02 · Sale (S): 51,750 @ $54.02 · +8 more | EDGAR |
| 2026-04-29 | 4 | Quart Barry D — Director | Option exercise (M): 13,099 @ $14.33 · Sale (S): 13,099 @ $50.10 · Option exercise (M): 13,099 (derivative) @ $0 | EDGAR |
| 2026-04-13 | 4 | Moat Ross — CHIEF OPERATING OFFICER | Sale (S): 1,703 @ $46.69 | EDGAR |
| 2026-04-13 | 4 | Megna Michael R — CHIEF ACCOUNTING OFFICER | Sale (S): 6,625 @ $46.69 | EDGAR |
| 2026-04-08 | 4 | Tessari Eben — CHIEF STRATEGY OFFICER | Option exercise (M): 2,726 · Tax withholding (F): 846 @ $48.94 · Option exercise (M): 2,726 (derivative) @ $0 | EDGAR |
| 2026-04-08 | 4 | Moat Ross — CHIEF OPERATING OFFICER | Sale (S): 2,367 @ $48.58 · Option exercise (M): 2,477 · Tax withholding (F): 774 @ $48.94 · Option exercise (M): 2,477 (derivative) @ $0 | EDGAR |
| 2026-04-08 | 4 | Ragosa Mark — CHIEF FINANCIAL OFFICER | Option exercise (M): 2,694 · Tax withholding (F): 1,303 @ $48.94 · Option exercise (M): 2,694 (derivative) @ $0 | EDGAR |
| 2026-04-08 | 4 | Paolini John F. — CHIEF MEDICAL OFFICER | Option exercise (M): 2,497 · Tax withholding (F): 1,208 @ $48.94 · Option exercise (M): 2,497 (derivative) @ $0 | EDGAR |
| 2026-04-08 | 4 | Patel Sanj K — CHAIRMAN & CEO, Director | Option exercise (M): 7,278 @ $10.36 · Sale (S): 7,278 @ $50.01 · Option exercise (M): 9,991 · Tax withholding (F): 4,831 @ $48.94 · Option exercise (M): 7,278 (derivative) @ $0 · Option exercise (M): 9,991 (derivative) @ $0 | EDGAR |
| 2026-04-08 | 4 | Megna Michael R — CHIEF ACCOUNTING OFFICER | Option exercise (M): 3,932 @ $1 · Tax withholding (F): 1,666 @ $48.94 · Option exercise (M): 3,932 (derivative) @ $0 | EDGAR |
| 2026-04-08 | 4 | Quart Barry D — Director | Option exercise (M): 6,901 @ $14.33 · Sale (S): 6,901 @ $50 · Option exercise (M): 6,901 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | Tessari Eben — CHIEF STRATEGY OFFICER | Grant/award (A): 365 @ $24.16 · Option exercise (M): 5,975 · Tax withholding (F): 1,756 @ $48.13 · Grant/award (A): 33,200 (derivative) @ $0 · Grant/award (A): 8,300 (derivative) @ $0 · Grant/award (A): 16,600 (derivative) @ $0 · +3 more | EDGAR |
| 2026-04-03 | 4 | Moat Ross — CHIEF OPERATING OFFICER | Grant/award (A): 879 @ $24.16 · Option exercise (M): 5,808 · Tax withholding (F): 1,706 @ $48.13 · Grant/award (A): 36,950 (derivative) @ $0 · Grant/award (A): 9,250 (derivative) @ $0 · Grant/award (A): 18,500 (derivative) @ $0 · +3 more | EDGAR |
| 2026-04-03 | 4 | Ragosa Mark — CHIEF FINANCIAL OFFICER | Option exercise (M): 5,187 · Tax withholding (F): 2,510 @ $48.13 · Grant/award (A): 31,150 (derivative) @ $0 · Grant/award (A): 7,800 (derivative) @ $0 · Grant/award (A): 15,600 (derivative) @ $0 · Option exercise (M): 1,750 (derivative) @ $0 · +2 more | EDGAR |
| 2026-04-03 | 4 | Paolini John F. — CHIEF MEDICAL OFFICER | Option exercise (M): 5,831 · Tax withholding (F): 2,821 @ $48.13 · Grant/award (A): 26,750 (derivative) @ $0 · Grant/award (A): 6,700 (derivative) @ $0 · Grant/award (A): 13,400 (derivative) @ $0 · Option exercise (M): 1,624 (derivative) @ $0 · +2 more | EDGAR |
| 2026-04-03 | 4 | Patel Sanj K — CHAIRMAN & CEO, Director | Option exercise (M): 21,327 · Tax withholding (F): 10,313 @ $48.13 · Grant/award (A): 120,150 (derivative) @ $0 · Grant/award (A): 30,050 (derivative) @ $0 · Grant/award (A): 60,100 (derivative) @ $0 · Option exercise (M): 6,481 (derivative) @ $0 · +2 more | EDGAR |
| 2026-04-03 | 4 | Megna Michael R — CHIEF ACCOUNTING OFFICER | Grant/award (A): 372 @ $24.16 · Option exercise (M): 7,564 · Tax withholding (F): 3,205 @ $48.13 · Grant/award (A): 14,600 (derivative) @ $0 · Grant/award (A): 3,650 (derivative) @ $0 · Grant/award (A): 7,300 (derivative) @ $0 · +3 more | EDGAR |
| 2026-03-11 | 4 | Ragosa Mark — CHIEF FINANCIAL OFFICER | Option exercise (M): 2,036 @ $22.89 · Option exercise (M): 10,513 @ $17.76 · Option exercise (M): 13,813 @ $18.06 · Option exercise (M): 10,360 @ $26.74 · Sale (S): 17,981 @ $45.58 · Sale (S): 18,741 @ $46.24 · +4 more | EDGAR |
| 2026-03-04 | 4 | Paolini John F. — CHIEF MEDICAL OFFICER | Option exercise (M): 40,000 @ $10.36 · Sale (S): 12,063 @ $44.20 · Sale (S): 22,223 @ $44.88 · Sale (S): 5,714 @ $45.92 · Option exercise (M): 40,000 (derivative) @ $0 | EDGAR |
| 2026-02-12 | 4 | Quart Barry D — Director | Option exercise (M): 110 @ $15.47 · Sale (S): 110 @ $45 · Option exercise (M): 2,690 @ $15.47 · Sale (S): 2,690 @ $45 · Option exercise (M): 110 (derivative) @ $0 · Option exercise (M): 2,690 (derivative) @ $0 | EDGAR |
| 2026-02-11 | 4 | Ragosa Mark — CHIEF FINANCIAL OFFICER | Option exercise (M): 8,374 @ $12.97 · Option exercise (M): 2,471 @ $16.90 · Sale (S): 9,114 @ $42.85 · Sale (S): 8,731 @ $43.72 · Option exercise (M): 8,374 (derivative) @ $0 · Option exercise (M): 2,471 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Levy Richard S — Director | Option exercise (M): 683 · Grant/award (A): 683 (derivative) @ $0 · Option exercise (M): 683 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Quart Barry D — Director | Option exercise (M): 830 @ $15.47 · Sale (S): 830 @ $45 · Option exercise (M): 12,528 @ $15.47 · Sale (S): 12,528 @ $45.27 · Option exercise (M): 2,602 @ $15.47 · Sale (S): 2,602 @ $45.02 · +3 more | EDGAR |
| 2026-01-09 | 4 | Ragosa Mark — CHIEF FINANCIAL OFFICER | Sale (S): 12,000 @ $41.89 | EDGAR |
| 2025-12-17 | 4 | Tessari Eben — CHIEF OPERATING OFFICER | Option exercise (M): 6,000 @ $8.83 · Sale (S): 12,048 @ $41.56 · Option exercise (M): 6,000 (derivative) @ $0 | EDGAR |
| 2025-12-17 | 4 | Quart Barry D — Director | Option exercise (M): 20,129 @ $10.36 · Sale (S): 20,129 @ $41.51 · Option exercise (M): 20,129 (derivative) @ $0 | EDGAR |
| 2025-12-10 | 4 | Ragosa Mark — CHIEF FINANCIAL OFFICER | Option exercise (M): 16,164 @ $11.10 · Option exercise (M): 16,165 @ $11.97 · Option exercise (M): 10,512 @ $10.76 · Sale (S): 42,841 @ $41.49 · Option exercise (M): 16,164 (derivative) @ $0 · Option exercise (M): 16,165 (derivative) @ $0 · +1 more | EDGAR |
| 2025-12-01 | 4 | Tessari Eben — CHIEF OPERATING OFFICER | Option exercise (M): 200 @ $22.89 · Sale (S): 200 @ $42.89 · Option exercise (M): 200 (derivative) @ $0 | EDGAR |
| 2025-11-19 | 4 | Tessari Eben — CHIEF OPERATING OFFICER | Option exercise (M): 6,500 @ $8.83 · Sale (S): 645 @ $40.08 · Sale (S): 11,825 @ $41.30 · Option exercise (M): 6,500 (derivative) @ $0 | EDGAR |
| 2025-11-14 | 4 | Ragosa Mark — CHIEF FINANCIAL OFFICER | Option exercise (M): 19,900 @ $30.93 · Sale (S): 19,900 @ $40.94 · Option exercise (M): 19,900 (derivative) @ $0 | EDGAR |
| 2025-11-14 | 4 | Patel Sanj K — CHAIRMAN & CEO, Director | Gift (G): 111,794 @ $0 · Gift (G): 111,794 @ $0 · Gift (G): 60,000 @ $0 · Gift (G): 60,000 @ $0 | EDGAR |
| 2025-11-04 | 4 | Paolini John F. — CHIEF MEDICAL OFFICER | Option exercise (M): 36,542 @ $3.80 · Option exercise (M): 46,000 @ $8.83 · Sale (S): 82,542 @ $37.14 · Option exercise (M): 36,542 (derivative) @ $0 · Option exercise (M): 46,000 (derivative) @ $0 | EDGAR |
| 2025-10-30 | 4 | Ragosa Mark — CHIEF FINANCIAL OFFICER | Option exercise (M): 100 @ $30.93 · Sale (S): 100 @ $41 · Option exercise (M): 100 (derivative) @ $0 | EDGAR |
| 2025-10-22 | 4 | Patel Sanj K — CHAIRMAN & CEO, Director | Option exercise (M): 121,248 @ $3.80 · Sale (S): 98,934 @ $38.81 · Sale (S): 22,314 @ $39.32 · Option exercise (M): 39,331 @ $3.80 · Sale (S): 39,331 @ $38.77 · Option exercise (M): 97,390 @ $3.80 · +4 more | EDGAR |
| 2025-10-22 | 4 | Megna Michael R — CHIEF ACCOUNTING OFFICER | Option exercise (M): 791 @ $15.50 · Option exercise (M): 6,195 @ $12.97 · Option exercise (M): 9,831 @ $11.10 · Option exercise (M): 9,831 @ $11.97 · Option exercise (M): 12,787 @ $10.76 · Sale (S): 37,255 @ $38.72 · +6 more | EDGAR |
| 2025-10-16 | 4 | Tessari Eben — CHIEF OPERATING OFFICER | Option exercise (M): 6,500 @ $8.83 · Sale (S): 11,815 @ $37.65 · Sale (S): 553 @ $37.99 · Option exercise (M): 6,500 (derivative) @ $0 | EDGAR |
Recent 8-K events — Kiniksa Pharmaceuticals International, plc
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-07-28 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-29 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-26 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-01 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-04-28 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-24 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-14 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-01-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-28 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-03 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=KNSA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →